[go: up one dir, main page]

WO2003000695A8 - Pyrrolopyrimidines as protein kinase inhibitors - Google Patents

Pyrrolopyrimidines as protein kinase inhibitors

Info

Publication number
WO2003000695A8
WO2003000695A8 PCT/GB2002/002835 GB0202835W WO03000695A8 WO 2003000695 A8 WO2003000695 A8 WO 2003000695A8 GB 0202835 W GB0202835 W GB 0202835W WO 03000695 A8 WO03000695 A8 WO 03000695A8
Authority
WO
WIPO (PCT)
Prior art keywords
pyrrolopyrimidines
protein kinase
kinase inhibitors
compounds
prodrugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/002835
Other languages
French (fr)
Other versions
WO2003000695A1 (en
Inventor
Paul Joseph Cox
Tahir Nadeem Majid
Shelley Amendola
Stephanie Daniele Deprets
Chris Edlin
Brian Leslie Pedgrift
Frank Halley
Michael Edwards
Bernard Baudoin
Iain Mcfarlane Mclay
David John Aldous
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UA2004010502A priority Critical patent/UA76760C2/en
Priority to EEP200400003A priority patent/EE05432B1/en
Priority to KR1020037016809A priority patent/KR100875380B1/en
Priority to HU0400300A priority patent/HUP0400300A3/en
Priority to SK1588-2003A priority patent/SK15882003A3/en
Priority to HR20031049A priority patent/HRP20031049A2/en
Priority to CA002451932A priority patent/CA2451932C/en
Priority to JP2003507098A priority patent/JP4344607B2/en
Priority to MXPA03011998A priority patent/MXPA03011998A/en
Priority to EA200400073A priority patent/EA007415B1/en
Priority to EP02740895A priority patent/EP1404676A1/en
Priority to AU2002314325A priority patent/AU2002314325B8/en
Priority to NZ529766A priority patent/NZ529766A/en
Priority to MEP-193/08A priority patent/MEP19308A/en
Priority to BR0210652-3A priority patent/BR0210652A/en
Priority to YU99203A priority patent/RS51698B/en
Priority to HK05100184.1A priority patent/HK1068134B/en
Priority to IL15950602A priority patent/IL159506A0/en
Priority to APAP/P/2003/002929A priority patent/AP2003002929A0/en
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of WO2003000695A1 publication Critical patent/WO2003000695A1/en
Priority to NO20035728A priority patent/NO20035728L/en
Priority to IL159506A priority patent/IL159506A/en
Priority to US10/744,478 priority patent/US7259154B2/en
Anticipated expiration legal-status Critical
Publication of WO2003000695A8 publication Critical patent/WO2003000695A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

This invention is directed to compounds of the formula (I) to N-oxides, prodrugs, acid bioisosteres, pharmaceutically acceptable salts or solvates of such compounds, or N-oxides, prodrugs, or acid bioisosteres of such salts or solvates, to compositions comprising such compounds, and to methods of treatment comprising administering, to a patient in need thereof, such compounds and compositions.
PCT/GB2002/002835 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors Ceased WO2003000695A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
NZ529766A NZ529766A (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
KR1020037016809A KR100875380B1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidine as a Protein Kinase Inhibitor
HU0400300A HUP0400300A3 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
SK1588-2003A SK15882003A3 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
HR20031049A HRP20031049A2 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
CA002451932A CA2451932C (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
JP2003507098A JP4344607B2 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
MXPA03011998A MXPA03011998A (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors.
EA200400073A EA007415B1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
EP02740895A EP1404676A1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
BR0210652-3A BR0210652A (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
UA2004010502A UA76760C2 (en) 2001-06-23 2002-06-21 Pyrrole pyrimidines as protein kinase inhibitors
MEP-193/08A MEP19308A (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
AU2002314325A AU2002314325B8 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
YU99203A RS51698B (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as Protein Kinase Inhibitors
HK05100184.1A HK1068134B (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
IL15950602A IL159506A0 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
APAP/P/2003/002929A AP2003002929A0 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors
EEP200400003A EE05432B1 (en) 2001-06-23 2002-06-21 P rrolop rimidines as protein kinase inhibitors
NO20035728A NO20035728L (en) 2001-06-23 2003-12-19 Pyrrolopyrimidines as protein kinase inhibitors
IL159506A IL159506A (en) 2001-06-23 2003-12-22 Pyrrolopyrimidines as protein kinase inhibitors
US10/744,478 US7259154B2 (en) 2001-06-23 2003-12-23 Pyrrolopyrimidines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0115393.1A GB0115393D0 (en) 2001-06-23 2001-06-23 Chemical compounds
GB0115393.1 2001-06-23
US30167801P 2001-06-28 2001-06-28
US60/301,678 2001-06-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/744,478 Continuation US7259154B2 (en) 2001-06-23 2003-12-23 Pyrrolopyrimidines

Publications (2)

Publication Number Publication Date
WO2003000695A1 WO2003000695A1 (en) 2003-01-03
WO2003000695A8 true WO2003000695A8 (en) 2004-03-11

Family

ID=9917225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/002835 Ceased WO2003000695A1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors

Country Status (22)

Country Link
EP (1) EP1404676A1 (en)
JP (1) JP4344607B2 (en)
CN (1) CN1294135C (en)
AU (1) AU2002314325B8 (en)
BR (1) BR0210652A (en)
CA (1) CA2451932C (en)
CZ (1) CZ20033443A3 (en)
EA (1) EA007415B1 (en)
EC (1) ECSP034922A (en)
EE (1) EE05432B1 (en)
GB (1) GB0115393D0 (en)
HU (1) HUP0400300A3 (en)
ME (1) MEP19308A (en)
NZ (1) NZ529766A (en)
OA (1) OA12632A (en)
PL (1) PL374096A1 (en)
RS (1) RS51698B (en)
SK (1) SK15882003A3 (en)
TN (1) TNSN03144A1 (en)
TR (1) TR200302242T2 (en)
UA (1) UA76760C2 (en)
WO (1) WO2003000695A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435814B2 (en) 2002-02-01 2008-10-14 Rigel Pharmaceuticals, Inc. 2,4-Pyrimidinediamine compounds and their uses
US7452879B2 (en) 2003-07-30 2008-11-18 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US8933086B2 (en) 2005-12-13 2015-01-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9216984B2 (en) 2009-05-22 2015-12-22 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9334274B2 (en) 2009-05-22 2016-05-10 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9359358B2 (en) 2011-08-18 2016-06-07 Incyte Holdings Corporation Cyclohexyl azetidine derivatives as JAK inhibitors
US9464088B2 (en) 2010-03-10 2016-10-11 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
DK1534286T3 (en) 2002-07-29 2010-04-26 Rigel Pharmaceuticals Inc Methods for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
EP1687309A1 (en) 2003-11-17 2006-08-09 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
EP1689407A1 (en) * 2003-11-25 2006-08-16 Pfizer Products Inc. Method of treatment of atherosclerosis
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
JP2008510734A (en) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド Kinase inhibitor
FR2876103B1 (en) 2004-10-01 2008-02-22 Aventis Pharma Sa NOVEL BIS-AZAINDOL DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
ATE479687T1 (en) 2004-10-15 2010-09-15 Takeda Pharmaceutical KINASE INHIBITORS
FR2878849B1 (en) 2004-12-06 2008-09-12 Aventis Pharma Sa SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
JP2008543855A (en) 2005-06-13 2008-12-04 ライジェル ファーマシューティカルズ， インコーポレイテッド Methods and compositions for treating degenerative bone disease
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
MX342814B (en) 2007-06-13 2016-10-13 Incyte Holdings Corp Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]py rimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile.
GEP20135780B (en) 2008-01-11 2013-03-11 Natco Pharma Ltd Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer agents
EP3031324A3 (en) 2008-06-10 2016-09-07 AbbVie Inc. Tricyclic kinase inhibitors
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc HETEROARYARY INHIBITORS OF BTK
CN102711476B (en) 2009-12-01 2014-12-03 Abbvie公司 Novel tricyclic compounds
EP3087972A1 (en) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topical formulation for a jak inhibitor
CN102093364B (en) 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 2,4-diamido-6,7-dihydro-5H-pyrrolo [2,3] pyrimidine derivative as focal adhesion kinase/pyruvate kinase 2 (FAK/Pyk2) inhibitor
CN103476776B (en) * 2011-01-07 2016-09-28 北京赛林泰医药技术有限公司 2,4-diaminourea-6,7-dihydro-5H-pyrrolo-[2,3] pyrimidine derivatives as FAK/Pyk2 inhibitor
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
CA2869954C (en) 2012-04-20 2023-01-03 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity
PL2877467T3 (en) 2012-07-26 2017-08-31 Glaxo Group Limited 2-(azaindol-2-yl)benzimidazoles as pad4 inhibitors
CA2883894C (en) 2012-09-06 2020-08-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TW202228704A (en) 2012-11-15 2022-08-01 美商英塞特控股公司 Sustained-release dosage forms of ruxolitinib
BR112015021549A2 (en) 2013-03-13 2017-07-18 Abbvie Inc pyridine kinase cdk9 inhibitors
BR112015023013A2 (en) 2013-03-13 2017-07-18 Abbvie Inc cdk9 kinase inhibitors
CN105189512A (en) * 2013-03-14 2015-12-23 艾伯维公司 Pyrrolopyrimindine CDK9 kinase inhibitors
TW201444836A (en) 2013-03-14 2014-12-01 Abbvie Inc Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors
BR112015023356A2 (en) 2013-03-14 2017-07-18 Abbvie Inc pyrrol [2,3-b] pyridine cdk9 kinase inhibitors
DK3030227T3 (en) 2013-08-07 2020-04-20 Incyte Corp RELEASING RELEASE DOSAGE FORMS FOR A JAK1 INHIBITOR
CN104804001B9 (en) * 2014-01-24 2022-02-08 江苏柯菲平医药股份有限公司 4-substituted pyrrolo [2,3-d ] pyrimidine compounds and uses thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN116270646A (en) 2015-10-16 2023-06-23 艾伯维公司 Process for preparing imidazo[1,2-a]pyrrolo[2,3-e]pyrazines and their solid state forms
EP4487908A3 (en) 2017-03-09 2025-01-15 AbbVie Inc. Methods of treating crohn's disease and ulcerative colitis
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
AR113922A1 (en) 2017-12-08 2020-07-01 Incyte Corp LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
CA3089832A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
IL318069A (en) 2018-03-30 2025-02-01 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
IL316875A (en) 2018-10-05 2025-01-01 Annapurna Bio Inc Compounds and compositions for treating conditions associated with apj receptor activity
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2177925T3 (en) * 1996-01-23 2002-12-16 Novartis Ag PIRROLOPIRIMIDINAS AND PROCEDURES FOR THEIR PREPARATION.
BR9713552A (en) * 1996-11-27 2000-01-25 Pfizer Condensed bicyclic pyrimidine derivatives
ATE265458T1 (en) * 1998-06-19 2004-05-15 Pfizer Prod Inc PYRROLO(2,3-D)PYRIMIDINE COMPOUNDS
PA8474101A1 (en) * 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
BR9913888A (en) * 1998-09-18 2002-01-08 Basf Ag Compound, and, methods of inhibiting protein kinase activity, treating a patient who has a condition that is mediated by protein kinase activity and decreasing fertility in a patient
HRP20020509B1 (en) * 1999-12-10 2005-06-30 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7557210B2 (en) 2002-02-01 2009-07-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7435814B2 (en) 2002-02-01 2008-10-14 Rigel Pharmaceuticals, Inc. 2,4-Pyrimidinediamine compounds and their uses
US7452879B2 (en) 2003-07-30 2008-11-18 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7582648B2 (en) 2003-07-30 2009-09-01 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US9206187B2 (en) 2005-12-13 2015-12-08 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase
US8933086B2 (en) 2005-12-13 2015-01-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
US8946245B2 (en) 2005-12-13 2015-02-03 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9334274B2 (en) 2009-05-22 2016-05-10 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9216984B2 (en) 2009-05-22 2015-12-22 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9464088B2 (en) 2010-03-10 2016-10-11 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US9023840B2 (en) 2011-06-20 2015-05-05 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9359358B2 (en) 2011-08-18 2016-06-07 Incyte Holdings Corporation Cyclohexyl azetidine derivatives as JAK inhibitors
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9221845B2 (en) 2013-03-06 2015-12-29 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1

Also Published As

Publication number Publication date
JP2005508300A (en) 2005-03-31
CN1294135C (en) 2007-01-10
UA76760C2 (en) 2006-09-15
AU2002314325B2 (en) 2009-01-08
ECSP034922A (en) 2004-04-28
HUP0400300A2 (en) 2007-08-28
TNSN03144A1 (en) 2005-12-23
JP4344607B2 (en) 2009-10-14
CA2451932C (en) 2009-12-29
AU2002314325B8 (en) 2009-01-29
BR0210652A (en) 2004-08-10
CN1518552A (en) 2004-08-04
EA200400073A1 (en) 2004-08-26
EA007415B1 (en) 2006-10-27
EE05432B1 (en) 2011-06-15
CZ20033443A3 (en) 2004-03-17
TR200302242T2 (en) 2004-12-21
WO2003000695A1 (en) 2003-01-03
RS51698B (en) 2011-10-31
NZ529766A (en) 2008-11-28
HUP0400300A3 (en) 2010-12-28
PL374096A1 (en) 2005-09-19
OA12632A (en) 2006-06-14
RS99203A (en) 2006-12-15
CA2451932A1 (en) 2003-01-03
MEP19308A (en) 2010-06-10
SK15882003A3 (en) 2004-07-07
EE200400003A (en) 2004-02-16
EP1404676A1 (en) 2004-04-07
GB0115393D0 (en) 2001-08-15

Similar Documents

Publication Publication Date Title
WO2003000695A8 (en) Pyrrolopyrimidines as protein kinase inhibitors
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
ES2195785A1 (en) Pyridazin-3(2h)-one derivatives as pde4 inhibitors
YU84603A (en) Novel tyrosine kinase inhibitors
GB0112348D0 (en) Compounds
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
WO2005049581A8 (en) Pyridazin-3 (2h) -one derivatives and their use as pde4 inhibitors
WO2004005281A8 (en) Inhibitors of tyrosine kinases
MXPA02005844A (en) Inhibitors of protein kinases.
WO2006011050A3 (en) Pyridine derivatives
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
WO2004058769A3 (en) Triazolopyridazines as protein kinases inhibitors
JO2372B1 (en) Prodrugs of 4-phenyl-pyridine derivatives
MXPA03010761A (en) Pharmaceutical combinations.
WO2002018321A3 (en) Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
WO2002081728A3 (en) Quinoline inhibitors of hyak1 and hyak3 kinases
WO2003051838A3 (en) Protein kinase inhibitors
DE50211929D1 (en) Pyrimidinderivate
MXPA04003611A (en) Piperidine- and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-992/03

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: DZP2003000281

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 529766

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003/09315

Country of ref document: ZA

Ref document number: 1-2003-501226

Country of ref document: PH

Ref document number: 200309315

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: AP/P/2003/002929

Country of ref document: AP

ENP Entry into the national phase

Ref document number: 10845302

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 028119320

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PV2003-3443

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: P20031049A

Country of ref document: HR

Ref document number: 2451932

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002314325

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 15882003

Country of ref document: SK

Ref document number: PA/A/2003/011998

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 159506

Country of ref document: IL

Ref document number: 374096

Country of ref document: PL

Ref document number: 2030/CHENP/2003

Country of ref document: IN

Ref document number: 1200301156

Country of ref document: VN

Ref document number: 2003507098

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003/02242

Country of ref document: TR

Ref document number: 10744478

Country of ref document: US

Ref document number: 1020037016809

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002740895

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200400073

Country of ref document: EA

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 01/2003 UNDER (75) REPLACE "ALDOUS, DAVIS, JOHN" BY "ALDOUS, DAVID, JOHN"

WWP Wipo information: published in national office

Ref document number: PV2003-3443

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2002740895

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 01/2003 UNDER (72, 75) REPLACE "AMENDOLA, SHELLEY" BY "AMENDOLA, SHELLEY" AND "MCLAY, LAIN, MCFARLANE" BY "MCLAY, IAIN, MCFARLANE.